The following represents disclosure information provided by authors of this abstract. The program committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered compensated. Relationships are self-held unless otherwise noted. I = Immediate Family Member, Inst = My Institution
 
Open Payments is a public database containing information reported by companies about payments made to US-licensed physicians (Open Payments)
 
 
Employment - ImmunoGenesis
Leadership - ImmunoGenesis
Stock and Other Ownership Interests - ImmunoGenesis
Honoraria - GLG Consulting Projects
Consulting or Advisory Role - GLG Consulting Projects; Tezcat Biosciences
Patents, Royalties, Other Intellectual Property - ImmunoGenesis
A phase 1a/1b study to evaluate the safety, tolerability, pharmacokinetics, and anti-tumor activity of IMGS-001 in patients with relapsed or refractory advanced solid tumors.
 
David Hong
Employment - MD Anderson Cancer Center
Stock and Other Ownership Interests - crossbridge Bio; MolecularMatch; OncoResponse; Telperian
Consulting or Advisory Role - Amgen; Bayer; BeiGene; Bristol Myers Squibb Company; Janssen; Mirati Therapeutics; Sanofi and Genzyme US Companies
Research Funding - Abbvie (Inst); Amgen (Inst); Bayer (Inst); Bristol Myers Squibb (Inst); Deciphera Pharmaceuticals Inc. (Inst); Genentech (Inst); Incyte (Inst); Merck Sharp & Dohme LLC (Inst); Mirati Therapeutics (Inst); Novartis (Inst); Pfizer (Inst)
Travel, Accommodations, Expenses - AACR; ASCO; Bayer Schering Pharma; CLCC; Genmab; Society for Immunotherapy of Cancer; Telperian
 
Shiraj Sen
No Relationships to Disclose
 
Charles Schweizer
Employment - ImmunoGenesis
Stock and Other Ownership Interests - ImmunoGenesis
Research Funding - ImmunoGenesis
Travel, Accommodations, Expenses - ImmunoGenesis
 
Amanda Sanders
Employment - ImmunoGenesis
Stock and Other Ownership Interests - ImmunoGenesis
Research Funding - ImmunoGenesis
 
Chelsey Grimes
Employment - ImmunoGenesis
Stock and Other Ownership Interests - ImmunoGenesis
Research Funding - ImmunoGenesis
 
Federica Pericle
Employment - ImmunoGenesis
Leadership - ImmunoGenesis
Stock and Other Ownership Interests - ImmunoGenesis
Honoraria - ImmunoGenesis
Consulting or Advisory Role - ImmunoGenesis
Patents, Royalties, Other Intellectual Property - ImmunoGenesis
 
Christine Gagliardi
Employment - ImmunoGenesis
Stock and Other Ownership Interests - ImmunoGenesis
Research Funding - ImmunoGenesis
 
James Barlow
No Relationships to Disclose
 
Ahmed Salameh
Employment - ImmunoGenesis
Stock and Other Ownership Interests - ImmunoGenesis
Research Funding - ImmunaGenesis
 
Michael Curran
Leadership - ImmunoGenesis
Stock and Other Ownership Interests - Agenus (I); Elicio Therapeutics (I); ImmunoGenesis; Relay Therapeutics (I)
Consulting or Advisory Role - Agenus; Alligator Bioscience; AstraZeneca/MedImmune; Everest Medicine; ImmunOs Therapeutics; OncoResponse; Xencor
Research Funding - ImmunoGenesis
Patents, Royalties, Other Intellectual Property - The Regents of the University of California, James Allison and Michael Curran. Methods and Composition for Localized Secretion of Anti-CTLA-4 Antibodies, United States, US 9,868,961 B2.; The University of Texas MD Anderson Cancer Center, Philip Jones, Maria Emilia DiFrancesco, Michael A. Curran. Cyclic Dinucleotides as Agonists of Stimulator of Interferon Gene Dependent Signaling, United States, 62/461,642.; The University of Texas, MD Anderson Cancer Center, Michael A. Curran, Carlo Toniatti, Ashvin R. Jaiswal, Dongxing Zha, and Voo Kui. Dual specificity antibodies which bind both PD-L1 and PD-L2 and prevent their binding to PD-1, United States, PCT/US2019/0
Travel, Accommodations, Expenses - AstraZeneca/MedImmune